Communiqués Sight Sciences, Inc.

Actions

SGHT

US82657M1053

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 31/05/2024			Varia. 5j.	Varia. 1 janv.
6,56 ^USD	+0,61 %		+17,77 %	+27,13 %

28/05	Sight Sciences, Inc. annonce la publication d'une nouvelle analyse de l'étude ROMEO montrant des réductions significatives de la pression et des médicaments obtenues avec Omni® ? dans les cas de glaucome léger, modéré et avancé	CI
14/05	Transcript : Sight Sciences, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 08:15 AM

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Sight Sciences Announces Publication of a New Analysis from the ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI across Mild, Moderate, and Advanced Glaucoma	29/05	AQ
Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis	28/05	AQ
Sight Sciences Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI® Across Mild, Moderate, and Advanced Glaucoma	28/05	AQ
Sight Sciences to Present at the Upcoming Bank of America Healthcare Conference	07/05	AQ
Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance	02/05	AQ
Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma Surgery	29/04	AQ
Sight Sciences : SGHT Proxy - Apr'24	26/04	PU
Sight Sciences to Report First Quarter Financial Results on May 2, 2024	18/04	AQ
Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma	10/04	GL
Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting	03/04	AQ
Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting	02/04	AQ
Sight Sciences to Present at the Upcoming 23rd Annual Needham Healthcare Conference	26/03	AQ
Sight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Initiates Full Year 2024 Financial Guidance	07/03	AQ
Sight Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024	22/02	AQ
Sight Sciences Announces European Launch of the Ergo-Series of the OMNI Surgical System at the ESCRS Winter Meeting	15/02	AQ
Sight Sciences Announces European Launch of the Ergo-Series of the OMNI® Surgical System at the ESCRS Winter Meeting	14/02	AQ
Sight Sciences Announces the Closing of up to $65 Million Senior Secured Credit Facility with Hercules Capital	23/01	AQ
Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Financial Highlights	08/01	AQ
Sight Sciences Announces Withdrawal of Final LCDs on Micro-Invasive Glaucoma Surgery from Five Medicare Administrative Contractors	28/12	AQ
Sight Sciences Announces the Publication of Successful Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease	18/12	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Sight Sciences, Inc.

Actions

SGHT

US82657M1053

Communiqués

Filtres